Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies (LQDA)
:LQDA
RESEARCH TOOLSreports
Holding LQDA?
Track your performance easily
LQDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.26 - $16.99
Previous CloseN/A
Volume97.81K
Average Volume (3M)804.49K
Market Cap
$1.06B
Enterprise Value$581.49M
Total Cash (Recent Filing)$1.44M
Total Debt (Recent Filing)$5.46M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 13, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding84,636,620
10 Day Avg. Volume806,674
30 Day Avg. Volume804,493
Standard Deviation0.20
R-Squared0.00338
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)67.83
Price to Cash Flow (P/CF)-10.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue37.25
Enterprise Value/Gross Profit39.83
Enterprise Value/Ebitda-5.42
Forecast
1Y Price Target
$25.86Price Target Upside106.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Liquidia Technologies News
PremiumCompany Announcements
Liquidia Corporation’s Q3 2024 Financial Highlights
Bulls Say, Bears Say
Bulls Say
FDA ApprovalA clear line of sight for FDA approval of Yutrepia in both PAH and PH-ILD.
Market OpportunityYutrepia will launch into a PAH/PH-ILD opportunity that will have grown into a $2B market.
Product DifferentiationYutrepia offers significant differentiation vs. Tyvaso DPI, including a superior inhaler device, higher dosing levels, improved tolerability, and potentially enhanced durability.
Bears Say
Legal ChallengesThe potential launch of Yutrepia faces uncertainty due to ongoing patent litigation, creating a legal overhang.
Product Launch UncertaintyThere is a lack of firm commitment to launch a key product, which could be impacted by unresolved patent issues.
Regulatory IssuesThe FDA's decision to delay the approval process by granting a 3-year exclusivity to a competing product has negatively impacted performance.
---
Ownership Overview
36.14% Insiders
5.55% Mutual Funds
0.02% Other Institutional Investors
49.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LQDA FAQ
What was Liquidia Technologies’s price range in the past 12 months?
Liquidia Technologies lowest stock price was $8.26 and its highest was $16.99 in the past 12 months.
What is Liquidia Technologies’s market cap?
Liquidia Technologies’s market cap is $1.06B.
When is Liquidia Technologies’s upcoming earnings report date?
Liquidia Technologies’s upcoming earnings report date is Mar 13, 2025 which is in 54 days.
How were Liquidia Technologies’s earnings last quarter?
Liquidia Technologies released its earnings results on Nov 13, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $0.074.
Is Liquidia Technologies overvalued?
According to Wall Street analysts Liquidia Technologies’s price is currently Undervalued.
Does Liquidia Technologies pay dividends?
Liquidia Technologies does not currently pay dividends.
What is Liquidia Technologies’s EPS estimate?
Liquidia Technologies’s EPS estimate is -0.38.
How many shares outstanding does Liquidia Technologies have?
Liquidia Technologies has 84,636,620 shares outstanding.
What happened to Liquidia Technologies’s price movement after its last earnings report?
Liquidia Technologies reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went down -3.387%.
Which hedge fund is a major shareholder of Liquidia Technologies?
Among the largest hedge funds holding Liquidia Technologies’s share is Farallon Capital Management, L.L.C.. It holds Liquidia Technologies’s shares valued at 33M.
---
Liquidia Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.86 (106.71% Upside)
$25.86 (106.71% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.02%
12-Months-Change
Fundamentals
Return on Equity
-150.73%
Trailing 12-Months
Asset Growth
126.52%
Trailing 12-Months
Company Description
Liquidia Technologies
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
---
LQDA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call expressed optimism about Liquidia's strategic and clinical progress, particularly in advancing YUTREPIA towards approval and expanding partnerships. However, ongoing legal challenges and increased expenses pose significant hurdles.Read More>---
LQDA Stock 12 Month Forecast
Average Price Target
$25.86
▲(106.71% Upside)
Technical Analysis
Kezar Life Sciences
―
ProQR
―
Verastem
―
Adaptimmune Therapeutics
―
Adverum Biotechnologies
―
Best Analysts Covering LQDA
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+45.59%
reiterated a buy rating 2 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +45.59% per trade.
---